Santarus Submits IND for Phase III Testing of Rifamycin in Travelers’ Diarrhea

Santarus, Inc., a specialty biopharmaceutical company, announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration requesting approval to begin a Phase III clinical program evaluating rifamycin SV MMX in patients with travelers’ diarrhea.
Fox Business